Literature DB >> 10537303

Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment.

J S Russell1, F F Lang, T Huet, M Janicot, S Chada, D R Wilson, P J Tofilon.   

Abstract

The expression of activated ras genes has been implicated as a contributing factor to the radioresistance of tumor cells. As a strategy for compromising Ras protein activity and potentially enhancing the radiosensitivity of tumor cells, we have investigated the application of the AV1Y28 adenovirus, which expresses a single-chain antibody fragment directed against p21 Ras proteins. The ability of AV1Y28 transduction to modulate radioresponse was investigated using four human tumor cell lines--U251 glioblastoma, MIA PaCa-2 pancreatic carcinoma, and the colon carcinomas SW620 and HT29. Cultures were exposed to sufficient levels of AV1Y28 to transduce more than 90% of the cells; 24 h later, cultures were exposed to ionizing radiation, and clonogenic cell survival was determined. Tumor cell survival was reduced by 40-50% when the tumor cell lines were exposed to AV1Y28 only. In addition, for each tumor cell line, AV1Y28 exposure enhanced the level of radiation-induced cell killing. Dose enhancement factors at a surviving fraction of 0.1 ranged from 1.3 to 1.5. Furthermore, for each of the cell lines, the surviving fraction at 2 Gy was significantly reduced by AV1Y28 exposure. In contrast to the results seen in tumor cells, the radiosensitivity of a normal human fibroblast cell line was not affected by AV1Y28. These data indicate that this anti-Ras adenovirus enhances the radiosensitivity of tumor cells but does not affect the radiosensitivity of normal cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537303

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Authors:  Kevin J Harrington; Eleni M Karapanagiotou; Victoria Roulstone; Katie R Twigger; Christine L White; Laura Vidal; Debbie Beirne; Robin Prestwich; Kate Newbold; Merina Ahmed; Khin Thway; Christopher M Nutting; Matt Coffey; Dean Harris; Richard G Vile; Hardev S Pandha; Johann S Debono; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

2.  Secreted Glioblastoma Nanovesicles Contain Intracellular Signaling Proteins and Active Ras Incorporated in a Farnesylation-dependent Manner.

Authors:  Natalie Luhtala; Aaron Aslanian; John R Yates; Tony Hunter
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

3.  Akt signaling pathway: a target for radiosensitizing human malignant glioma.

Authors:  Emmanuel Chautard; Gaëlle Loubeau; Andreï Tchirkov; Jacques Chassagne; Claudine Vermot-Desroches; Laurent Morel; Pierre Verrelle
Journal:  Neuro Oncol       Date:  2010-02-04       Impact factor: 12.300

4.  The actin-cytoskeleton pathway and its potential role in inflammatory bowel disease-associated human colorectal cancer.

Authors:  Ziad Kanaan; Motaz Qadan; Maurice Robert Eichenberger; Susan Galandiuk
Journal:  Genet Test Mol Biomarkers       Date:  2010-06

5.  Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches.

Authors:  David Mampre; Yusuf Mehkri; Shashank Rajkumar; Sai Sriram; Jairo Hernandez; Brandon Lucke-Wold; Vyshak Chandra
Journal:  Diagn Ther       Date:  2022-06-20

Review 6.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

7.  Influence of tumors on protective anti-tumor immunity and the effects of irradiation.

Authors:  Gemma A Foulds; Jürgen Radons; Mira Kreuzer; Gabriele Multhoff; Alan G Pockley
Journal:  Front Oncol       Date:  2013-02-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.